🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and st...
Status
Active Not Recruiting
Location
City of Hope Medical Center
Start Date
2018-08-29
Trial ID
NCT03361735
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays d...
Status
Completed
Location
Arizona Center for Cancer Care - Peoria
Start Date
2009-02
Trial ID
NCT00750269
This study will look at treatment for patients that have already been diagn...
Status
Recruiting
Location
Bon Secours/UPMC
Start Date
2023-11-21
Trial ID
NCT06078813
Treatments Being Tested
This is a 3+3 dose escalation phase I study which aims to evaluate the safe...
Status
Recruiting
Location
West China Hospital, Sichuan University
Start Date
2024-04-18
Trial ID
NCT06349837
Treatments Being Tested
To evaluate the benefit of SAbR for oligo-progressive metastatic urothelial...
Status
Terminated
Location
Aurelie Garant
Start Date
2020-01-16
Trial ID
NCT04131634
Treatments Being Tested
Stereotactic ablative body radiotherapy (SABR) can be considered for patien...
Status
Completed
Location
GZA St Augustinus
Start Date
2017-07-05
Trial ID
NCT03486431
Treatments Being Tested
This single arm trial will investigate a novel way to plan and deliver SABR...
Status
Active Not Recruiting
Location
Medical University of South Carolina Hollings Cancer Center
Start Date
2023-05-12
Trial ID
NCT05668351
Treatments Being Tested
The purpose of this study is to test whether 5 fraction stereotactic ablati...
Status
Terminated
Location
Indiana University Health Hospital
Start Date
2017-10-20
Trial ID
NCT03321747
Treatments Being Tested
Stereotactic ablative radiotherapy (SABR) is a new radiation treatment that...
Status
Completed
Location
London Health Sciences Centre - London Regional Cancer Program
Start Date
2020-11-17
Trial ID
NCT04530513